Valuation Metrics and Recent Changes
As of 1 June 2026, Lupin’s price-to-earnings (P/E) ratio stands at 18.03, a figure that positions the company favourably within its peer group. This P/E is below several competitors such as Zydus Lifesciences, which trades at a P/E of 19.91, and significantly lower than Mankind Pharma’s elevated 49.31. The price-to-book value (P/BV) ratio of 4.63 further underscores Lupin’s valuation appeal, balancing growth expectations with asset backing.
Other enterprise value (EV) multiples reinforce this perspective: EV to EBIT at 13.62 and EV to EBITDA at 11.49 indicate a reasonable premium relative to earnings before interest and taxes, and earnings before interest, taxes, depreciation, and amortisation, respectively. These multiples suggest that while Lupin is not the cheapest in the sector, it maintains an attractive valuation compared to more expensive peers like Laurus Labs (EV/EBITDA of 43.12) and Anthem Biosciences (49.26).
Peer Comparison Highlights
Within the Pharmaceuticals & Biotechnology sector, Lupin’s valuation metrics place it in the “attractive” category, a notch below its previous “very attractive” status but still favourable when contrasted with the broader market. For instance, Glenmark Pharma, rated as “very attractive,” trades at a higher P/E of 26.65, while Biocon, also “attractive,” commands a P/E of 94.1, reflecting differing growth trajectories and risk profiles.
The PEG ratio of 0.24 for Lupin is particularly noteworthy, indicating that the stock’s price is low relative to its earnings growth rate. This contrasts sharply with peers such as Zydus Lifesciences (PEG 1.23) and Mankind Pharma (PEG 32.55), suggesting Lupin offers a more compelling growth-adjusted valuation.
Financial Performance and Returns
Lupin’s financial health is robust, with a return on capital employed (ROCE) of 37.51% and return on equity (ROE) of 25.68%, both metrics signalling efficient capital utilisation and strong profitability. Dividend yield remains modest at 0.53%, reflecting the company’s focus on reinvestment and growth rather than income distribution.
Stock price performance relative to the Sensex further highlights Lupin’s resilience and growth potential. Year-to-date, Lupin has delivered a 7.6% return compared to the Sensex’s negative 12.26%. Over one year, Lupin’s stock has appreciated by 15.11%, outperforming the Sensex’s decline of 8.4%. Longer-term returns are even more impressive, with a three-year gain of 182.13% versus the Sensex’s 18.98%, and a five-year return of 88.02% compared to the benchmark’s 45.41%.
Rising fast and still accelerating! This Small Cap from FMCG sector is riding pure momentum right now. Jump in before the rally reaches its peak!
- - Accelerating price action
- - Pure momentum play
- - Pre-peak entry opportunity
Market Capitalisation and Trading Range
Lupin is classified as a mid-cap company, with its current share price at ₹2,272.45, slightly down by 0.19% from the previous close of ₹2,276.75. The stock has traded within a 52-week range of ₹1,838.65 to ₹2,492.00, indicating a relatively stable price band with room for upside given the current valuation and sector outlook.
Intraday volatility on 1 June 2026 saw Lupin’s price fluctuate between ₹2,258.60 and ₹2,301.00, reflecting moderate trading activity and investor interest. This stability is a positive sign for investors seeking exposure to pharmaceuticals with balanced risk-return profiles.
Valuation Grade Adjustment and Implications
The recent downgrade in Lupin’s valuation grade from “very attractive” to “attractive” on 25 May 2026 signals a subtle shift in market sentiment. While the stock remains a buy with a Mojo Score of 77.0, the adjustment suggests that some premium has been priced in, possibly due to improved sector-wide valuations or evolving growth expectations.
Despite this, Lupin’s valuation remains compelling relative to many peers, especially considering its strong fundamentals and consistent outperformance against the Sensex over multiple time horizons. Investors should weigh this grade change as a recalibration rather than a warning, recognising Lupin’s sustained competitive advantages and growth prospects.
Want to dive deeper on Lupin Ltd.? There's a real-time research report diving right into the fundamentals, valuations, peer comparison, financials, technicals and much more!
- - Real-time research report
- - Complete fundamental analysis
- - Peer comparison included
Sector Outlook and Investment Considerations
The Pharmaceuticals & Biotechnology sector continues to attract investor interest due to its defensive characteristics and growth driven by innovation and expanding healthcare needs. Lupin’s valuation metrics, combined with its strong returns on capital and equity, position it well to capitalise on sector tailwinds.
However, investors should remain mindful of competitive pressures from peers with varying valuation profiles and growth strategies. For example, companies like Laurus Labs and Anthem Biosciences trade at significantly higher multiples, reflecting either higher growth expectations or speculative premiums. Lupin’s more moderate valuation offers a balanced risk-return proposition.
Moreover, Lupin’s PEG ratio of 0.24 suggests undervaluation relative to earnings growth, a critical factor for long-term investors seeking sustainable appreciation rather than short-term speculation.
Conclusion
Lupin Ltd.’s recent valuation grade adjustment from very attractive to attractive reflects a maturing market view but does not diminish the company’s investment appeal. With a P/E of 18.03, robust profitability metrics, and consistent outperformance against the Sensex, Lupin remains a compelling buy within the Pharmaceuticals & Biotechnology sector.
Investors should consider Lupin’s valuation in the context of its strong fundamentals, peer comparisons, and sector dynamics. The stock’s moderate premium relative to earnings and book value, combined with a low PEG ratio, indicates that Lupin offers a favourable entry point for those seeking exposure to quality pharmaceutical companies with growth potential.
As always, monitoring sector developments and company-specific news will be essential to assess ongoing valuation attractiveness and investment suitability.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →
